非结核分枝杆菌感染中的治疗药物监测
非结核分枝杆菌感染治疗疗程长、方案复杂且毒性风险高,治疗药物监测可优化疗效并降低毒性。本综述汇总体外、体内及临床数据,给出各治疗药物的药代动力学/药效学靶值,以弥补缺乏随机对照试验证据的不足。
要点
- 非结核分枝杆菌病治疗失败率高,治疗药物监测是优化治疗的优良方法。
- 综述汇总体外、体内及临床数据,提出各药物的药代动力学/药效学靶值。
- 目前针对该病的治疗药物监测指导十分有限,本综述旨在填补这一空白。
核心结论
- 治疗药物监测可优化非结核分枝杆菌感染治疗的疗效并减少毒性。
- 因缺乏随机对照试验数据,本综述汇总体外、体内及临床数据以支持治疗药物监测建议。
研究设计与样本
- 综述汇总体外、体内及临床数据,以提出非结核分枝杆菌治疗药物的药代动力学/药效学靶值。
主要发现
- 非结核分枝杆菌感染治疗复杂、易获得性耐药、毒性高且治疗失败率高。
- 疗程长、多药联合方案及药物毒性风险使治疗药物监测成为优化治疗的优良方法。
关键数值与推荐
- 综述提供各治疗药物的药代动力学/药效学靶值信息,用于治疗药物监测建议。
临床怎么用
- 临床可基于本综述汇总的药代动力学/药效学靶值开展治疗药物监测,以提高疗效并降低毒性。
局限性
- 缺乏随机对照试验数据,建议基于汇总的体外、体内及临床数据。
- 目前针对该病的治疗药物监测指导有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nontuberculous mycobacteria can cause minimally symptomatic self-limiting infections to progressive and life-threatening disease of multiple organs. Several factors such as increased testing and prevalence have made this an emerging infectious disease. Multiple guidelines have been published to guide therapy, which remains difficult owing to the complexity of therapy, the potential for acquired resistance, the toxicity of treatment, and a high treatment failure rate. Given the long duration of therapy, complex multi-drug treatment regimens, and the risk of drug toxicity, therapeutic drug monitoring is an excellent method to optimize treatment. However, currently, there is little available guidance on therapeutic drug monitoring for this condition. The aim of this review is to provide information on the pharmacokinetic/pharmacodynamic targets for individual drugs used in the treatment of nontuberculous mycobacteria disease. Lacking data from randomized controlled trials, in vitro, in vivo, and clinical data were aggregated to facilitate recommendations for therapeutic drug monitoring to improve efficacy and reduce toxicity.
引用
- Alffenaar JW, Märtson AG, Heysell SK, et al. Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. Clin Pharmacokinet. 2021. PMID: 33751415. doi:10.1007/s40262-021-01000-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。